Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGAT1 | O75907 | 1/20 | 0.39 |
| ▸ | CYP4F2 | P78329 | 2/20 | 0.35 |
| ▸ | CYP4A11 | Q02928 | 2/20 | 0.35 |
| ▸ | MGAM | O43451 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | SI | P14410 | 1/20 | 0.35 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.35 |
| ▸ | PKM | P14618 | 3/20 | 0.33 |
| ▸ | MMP8 | P22894 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | THRB | P10828 | 1/20 | 0.31 |
| ▸ | KCNN4 | O15554 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | CA1 | P00915 | 1/20 | 0.30 |
| ▸ | CA2 | P00918 | 1/20 | 0.30 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10011399 | 0.83 | DGAT1 (0.32) | DGAT1CYP4F2CYP4A11 | |
| SCHEMBL6507050 | 0.80 | CYP4F2 (0.48) | CYP4F2CYP4A11MGAMGAASI | |
| SCHEMBL445544 | 0.80 | DGAT1 (0.39) | DGAT1CYP4F2CYP4A11MGAMGAA | |
| SCHEMBL27665143 | 0.78 | DGAT1 (0.43) | DGAT1CYP4F2CYP4A11ALDH1A1CA1 | |
| SCHEMBL19331262 | 0.78 | CYP4F2 (0.34) | CYP4F2CYP4A11ALDH1A1TSHR | |
| SCHEMBL15066109 | 0.78 | CYP4F2 (0.38) | CYP4F2CYP4A11PKMALDH1A1THRB | |
| SCHEMBL17353528 | 0.77 | MGAM (0.36) | CYP4F2CYP4A11MGAMGAASI | |
| SCHEMBL15951338 | 0.77 | MGAM (0.36) | DGAT1MGAMGAASIMGAM2 | |
| SCHEMBL27972010 | 0.76 | DGAT1 (0.37) | DGAT1CYP4F2CYP4A11MGAMGAA | |
| SCHEMBL4174244 | 0.75 | CYP4F2 (0.44) | CYP4F2CYP4A11MGAMGAASI |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-108997340-B | Synthetic method of 5-bromo-7-azaindole | 山东轩德医药科技有限公司 | 2020-03-20 | — | — | CN | claimed |
| CN-108997340-B | Synthetic method of 5-bromo-7-azaindole | 山东轩德医药科技有限公司 | 2020-03-20 | — | — | CN | disclosed |
| US-9493461-B2 | Tetracyclic heterocycle compounds and methods of use thereof for the treatment of hepatitis C | MERCK SHARP & DOHME CORP. (US) | 2016-11-15 | — | — | US | disclosed |
| US-20150368246-A1 | TETRACYCLIC HETEROCYCLE COMPOUNDS AND METHODS OF USE THEREOF FOR THE TREATMENT OF HEPATITIS C | MERCK SHARP & DOHME CORP. (US) | 2015-12-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150368246-A1 | TETRACYCLIC HETEROCYCLE COMPOUNDS AND METHODS OF USE THEREOF FOR THE TREATMENT OF HEPATITIS C | HCCS, HAVCR2, CYP7A1 | DGAT1 1129/4885CYP4F2 443/4885CYP4A11 588/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.